AskBio, a Bayer subsidiary, announced on Tuesday the start of patient enrolment in a Phase 2 clinical trial dedicated to the evaluation of its gene therapy for the treatment of Parkinson's disease.

This trial will follow 87 individuals aged 45 to 75 with a moderate form of the disease in the United States, Europe and the United Kingdom.

In January, the biopharmaceutical company announced that a Phase 1b trial conducted on 11 patients had met its primary endpoint, with good tolerance of the treatment and no serious side effects.

According to the Parkinson's Foundation, more than ten million people worldwide suffer from Parkinson's disease.

Copyright (c) 2024 CercleFinance.com. All rights reserved.